European Patients'Academy on Therapeutic Innovation
Budget
€821,911
EP Access
0
accredited persons
Staff
1
0.25 FTE
EU Grants
€238,710
Mission & Goals
EUPATI is a patient-led multistakeholder public-private partnership. Based on its original construct as a collaborative EU project, EUPATI partnership consists of patient organisations, academic institutions and pharmaceutical companies from Europe and all over the world. EUPATI develops and offers education and training for patients and other stakeholders in healthcare in order to enable meaningful patient involvement in therapeutic innovation. EUPATI realises its objective through, inter alia, a) the development and dissemination of accessible, well-structured, comprehensive, independent, scientifically reliable and user-friendly educational material and training for patients and other stakeholders, b) cross-institutional education and training for different stakeholders on Patient Engagement, c) procurement of grants, d) participation in projects, e) fundraising, f) the formation of international networks, g) facilitating interaction between partners.
EU Legislative Interests
Revision of EU Pharmaceutical Legislation, European Biotech Act, European Health Data Space (EHDS)
Communication Activities
EUPATI provides information and education for citizens, patients and patent representatives via its online Toolbox on Medicines R&D, online courses on its Open Classroom and its Patient Expert Training Programme resulting in a EUPATI Fellow certificate. EUPATI's syllabus includes non-clinical and clinical research, regulatory affairs, health technology assessment (HTA), medical devices and digital health. Through these efforts, EUPATI supports the involvement of patients in research, and facilitates collaboration among all stakeholders. EUPATI follows the EU legislative proposals, and updates its materials and trainings accordingly.
Interests Represented
Does not represent commercial interests
Member Of
N/A
Organisation Members
EUPATI is a public-private partnership composed of a multi-stakeholder structure representing patient organisations, not-for-profit, pharmaceutical industry and academic institutions. The current partners (as of 2025) are listed below. Full list available at https://eupati.eu/our-organisation/ European AIDS Treatment Group (EATG) European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) European Liver Patients' Association (ELPA) European Patients’ Forum (EPF) Parkinson’s Europe The International Alliance of Dermatology Patient Organizations (GlobalSkin) The Irish Platform for Patient Organisations, Science and Industry (IPPOSI) Digestive Cancers Europe (DICE) Drug Information Association (DIA) European Haemophilia Consortium (EHC) Global Heart Hub SMA Europe International Diabetes Federation Europe European Infrastructure for Translational Medicine (EATRIS) European Clinical Research Infrastructrure Network (ECRIN) European Forum for Good Clinical Practice (EFGCP) European Organisation for Research and Treatment of Cancer (EORTC) FindMeCure Foundation ISPOR KU Leuven Sant Joan de Deu Research Institute The Organisation for Professionals in Regulatory Affairs (TOPRA) South East Technological University (SETU) University College Dublin Vall d'Hebron University Hospital Innodia VAC4EU Abbvie Almirall Amgen AstraZeneca Bayer Boehringer Ingelheim Bristol-Myers Squibb Chiesi CSL Behring Daiichi Sankyo GlaxoSmithKline Incyte Johnson & Johnson Lundbeck Menarini MSD Novartis Pfizer Roche Servier Sobi Takeda UCB ViiV Healthcare
Additional Information
EUPATI received funding from the following EU programmes: COMBINE-CT (IHI, Nr 101132862), GEREMY (Horizon, Nr 101080204), HTA4Patients (EU4Health, Nr 101101156), SIMPATHIC (Horizon, Nr 101080249). 25 of the 27 member contributions received in 2024 were over 10,000 EUR but no contribution exceeded 3.3% of the total budget.
Commissioner Meetings
No recorded meetings with EU commissioners.